Skip to main content
. 2024 Sep 7;5(11):100720. doi: 10.1016/j.jtocrr.2024.100720

Table 2.

Exacerbation Pattern on Progression With Osimertinib

Progression Pattern Asymptomatic and No Clinical Exacerbation Symptomatic and No Clinical Exacerbation Clinical Exacerbationa Total
CNS metastasis only 16 4 17 37
(4.7) (1.2) (4.9) (10.8)
Oligoprogressionb 109 30 17 156
(31.7) (8.7) (4.9) (45.4)
Multiple organs 70 39 42 151
(20.4) (11.3) (12.2) (43.9)
Total 195 73 76 344
(56.7) (21.2) (22.1) (100)

Note: All values are n (%).

CNS, central nervous system; PS, performance status.

a

Clinical exacerbation was defined as a decline in the PS and or or exacerbation threatening major organs (carcinomatous lymphangiosis, bone marrow metastasis, carcinomatous meningitis, liver metastasis with liver damage, etc.).

b

Single organ other than the CNS (up to three per organ).